Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2023 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
October 18, 2023 21:16 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Proposed Public Offering of Common Stock
October 17, 2023 16:02 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
October 16, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx today will provide updates on its development pipeline and gene therapy portfolio at an Analyst Day in New York City and by webcast.
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
October 14, 2023 16:30 ET
|
Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
October 09, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx to share data from late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta at American Society for Bone and Mineral Research
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
October 05, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx will host Analyst Day webcast on Monday, October 16, 2023 to provide updates on programs for osteogenesis imperfecta, Angelman syndrome and more
Ultragenyx lance EVKEEZA (évinacumab pour injection) au Canada pour traiter l’hypercholestérolémie familiale homozygote (HFHo)
September 25, 2023 17:13 ET
|
Ultragenyx Pharmaceutical Inc.
TORONTO, 25 sept. 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ : RARE), compagnie biopharmaceutique spécialisée dans le développement et la commercialisation de nouveaux...
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
September 25, 2023 17:13 ET
|
Ultragenyx Pharmaceutical Inc.
TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...